In a recent transaction, Warren J. Nimetz, a director at Universal Health Services Inc (NYSE:UHS), sold 725 shares of the company's Class B Common Stock for $180.32 each, totaling over $130,732. This sale occurred on May 16, 2024, as reported in a new filing with the Securities and Exchange Commission.
The transaction comes after Nimetz acquired 1,097 shares of Universal Health Services through restricted stock units (RSUs) on May 15, 2024, at no cost. According to the footnotes in the SEC filing, these RSUs are part of the company's Amended and Restated 2020 Omnibus Stock and Incentive Plan and are set to vest on May 15, 2025.
Following these transactions, Nimetz's direct ownership in the company stands at 3,971 shares of Class B Common Stock. The shares sold by Nimetz were disposed of at a uniform price of $180.32, as indicated by the footnotes in the filing.
Investors often monitor insider transactions as they provide insights into executives' perspectives on the company's stock value and financial health. Universal Health Services specializes in general medical and surgical hospital services and is incorporated in Delaware. The company is headquartered in King of Prussia, Pennsylvania.
The SEC filing was signed on behalf of Mr. Nimetz by Steve Filton, attorney-in-fact, on May 16, 2024.
InvestingPro Insights
Universal Health Services Inc (NYSE:UHS) has recently been on the radar of investors and analysts for several reasons. As of the last twelve months leading up to Q1 2024, UHS has demonstrated a robust financial performance with a revenue growth of 7.99%, indicating a steady increase in its operational income. This is further evidenced by a healthy gross profit margin of 40.28%, showcasing the company's ability to maintain profitability amidst market fluctuations.
One of the noteworthy InvestingPro Tips for UHS is that it has maintained dividend payments for 22 consecutive years, which is a testament to its financial stability and commitment to shareholder returns. Another significant tip is that six analysts have revised their earnings upwards for the upcoming period, which may suggest a positive outlook on the company's future financial performance.
From a valuation standpoint, UHS is trading at a low P/E ratio of 15.03, which is attractive when paired with its near-term earnings growth. The company also boasts a PEG ratio of 0.59, which can be appealing to investors looking for growth at a reasonable price. Furthermore, with a market capitalization of $11.98 billion and a price close to its 52-week high, UHS appears to be a prominent player in the Healthcare Providers & Services industry.
For those interested in deeper analysis, there are additional InvestingPro Tips available on https://www.investing.com/pro/UHS. Readers can use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, gaining access to an extensive range of insights and data to inform their investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.